Objectives: To determine the incidence, presentation, and outcome of hyperlactatemia and lactic acidosis. Design and Methods Setting: Grey's Hospital, a tertiary level referral institution. Study Population: A chart review of 1719 patients commenced on highly active antiretroviral therapy (HAART) between August 1, 2004, and July 31, 2006. A total of 1000 patients (615 females) received stavudine (d4T)/lamivudine (3TC)/efavirenz (EFV), 719 patients (598 females) received d4T/ 3TC/nevirapine (NVP). Results: Of the 1719 patients, 152 (8.84%) had an elevated plasma venous lactate (>2.2 mmol/L), 45 patients required admission for lactic acidosis. The overall incidence rate was 13.5 cases per 1000 patient years. The most common presenting symptoms were loss of weight (95%), abdominal pain (78.9%), loss of appetite, and paresthesias (63.8%). The median body mass index (BMI) at commencement of HAART and at onset of symptoms was 24.5 and 26, respectively. A median serum lactate level of 6.08 mmol/L (range 2.3-19.7 mmol/L) was observed at the onset of symptoms. Conclusions: High BMI at treatment initiation did not always predict hyperlactatemia. All patients who died had a baseline CD4 count <10 cells/mm 3 at HAART initiation.
Introduction
The availability of highly active antiretroviral therapy (HAART) has reduced the morbidity and mortality associated with HIV infection and AIDS. 1, 2 The preferred initial therapies for HIV-1 infection include 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI).
The South African national HIV treatment guidelines recommend stavudine (d4T), lamivudine (3TC), and efavirenz (EFV; regimen 1a) or nevirapine (NVP; regimen 1b) as an initial treatment regimen and didanosine (ddI), zidovudine (AZT), and lopinavir/ritonavir (LPV/r) as the subsequent treatment regimen (regimen 2). Agents on regimen 2 are available for substitution for adverse events to agents in regimen 1 and for treatment failure following regimen 1 exposure. 3 The active intracellular anabolites of NRTIs block viral replication by competing with cellular nucleotides for incorporation into proviral DNA and are relatively specific for HIV reverse transcriptase. [3] [4] [5] The ability of NRTIs to inhibit human mitochondrial DNA is associated with toxicities namely, peripheral neuropathy, hepatic steatosis, lipoatrophy, and lactic acidosis syndrome. [6] [7] [8] [9] Hyperlactatemia is defined as a lactate level greater than 2.2 mmol/L and lactic acidosis is defined as a lactate level greater than 5 mmol/L together with a pH <7.35, and/or bicarbonate (HCO 3 ) <20 mmol/L and anion gap >20. This serious adverse event may result in severe metabolic acidosis, a life-threatening complication. In resource-rich countries, lactic acidosis is a rare side effect with reported incidence rates ranging between 1.3 and 10 episodes per 1000 person years on HAART. 9,10 A higher incidence of hyperlactatemia and lactic acidosis has been reported in South Africa and Botswana among women receiving d4T-containing treatment. [10] [11] [12] The purpose of this study was to determine the incidence rate, presentation, and outcome of hyperlactatemia and lactic acidosis in a tertiary communicable diseases clinic.
Material and Methods
Grey's Hospital is a tertiary referral institution for western Kwazulu-Natal and is located in Pietermaritzburg, Kwazulu-Natal, South Africa (SA). The communicable disease clinic is dedicated to comprehensive HIV care and serves as both an initiation and referral site. The clinic began providing antiretroviral treatment (ART) per the South African national HIV treatment guidelines on August 1, 2004.
Study Population
A retrospective chart review of 1719 (70.56% females) patients commenced on HAART, between August 1, 2004, and July 31, 2006, was undertaken. A total of 1000 patients (61.5% females) received d4T (40 mg twice-daily [bid])/3TC (150 mg bid)/EFV (600 mg at night) and 719 patients (83.17% females) received d4T (40 mg bid)/3TC (150 mg bid)/NVP (200 mg bid).
Procedures
In this cohort, patient monitoring includes monthly weight measurements and 6 monthly vital sign check, clinical, and laboratory monitoring: CD4 count, HIV RNA viral load, hematological, hepatic and renal function, and glucose measurements.
Blood is obtained by venepuncture for lactate estimation in patients with new onset (within the preceding 4 weeks) of any 1 of the symptoms or signs suggestive of hyperlactatemia or lactic acidosis viz abdominal pains, weight loss, paresthesias (sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect). The lactate sample is obtained by venepuncture without a tourniquet after the patient is at rest for at least 15 minutes. Screening of symptomatic patients is undertaken using a portable point of care device (Accutrend lactate meter, Roche Products (Pty) Ltd) and confirmed with laboratory measurement on the same sample. 13 Samples are obtained in a sodium fluoride tube and transported to the laboratory on ice within 40 minutes of venepuncture for confirmation of the lactate estimation. A repeat venous lactate measurement was obtained to confirm the initial elevated venous lactate measurement.
The diagnosis of hyperlactatemia of lactic acidosis was made after excluding other causes of hyperlactatemia or lactic acidosis such as renal failure, chronic diarrhea, sepsis, or liver failure.
Ethics
The chart review was approved by the Grey's Hospital Ethics Committee (reference number: EHRschApprvlDec08/Fjm).
Results

Baseline Characteristics of Patients
In this review, 152 (2.14%) patients had symptoms and an elevated plasma venous lactate (>2.2 mmol/L). Patients' characteristics are shown in Table 1 .
The mean age was 38 years + 9.07 (range 18-68 years). The majority of the patients (75.65%) were between 26 and 45 years. The median CD4 count at baseline was 79 cells/mm 3 (range 0-323 cells/mm 3 ), and the median viral load (VL) at baseline was 5.25 log copies/mL (range log copies/mL 2.69-6.39). A total of 64 patients required admission of which, 45 had lactic acidosis (41 females and 4 males).
The mean length of time on HAART before onset of symptoms was 9.2 months + 3.77. The majority of patients presented with symptoms within 13 months after starting HAART (67.7%). The median body mass index (BMI) at commencement of HAART was 24.9 kg/m 2 (+4.29; Table 1 ) and BMI at onset of symptoms was 26.7 kg/m 2 at presentation of hyperlactatemia and lactic acidosis.
A mean serum lactate level of 6.8 + 2.87 mmol/L (range 2.3-19.7 mmol/L) was observed at the onset of symptoms ( Table 2) . A higher rate of hyperlactatemia and lactic acidosis was observed among females compared to males and this is in keeping with previous reports. 11, 12 The incidence of hyperlactatemia/lactic acidosis between male and female patients is proportionally increasing according to lactate levels from 1:4 with lactate 2.3 to 5 mmol/L to 1:9 with lactate >10 mmol/L ( Table 2 ).
The overall incidence rate of lactic acidosis was 13.5 cases per 1000 patient years (95% confidence interval 9-29), and the overall incidence of hyperlactatemia without acidosis was 31.79 cases per 1000 patient years (95% confidence interval 14-40;. Table 2) The most common presenting symptoms were loss of weight (95.39%), abdominal pain (78.94%), loss of appetite, and paresthesias (63.81%; Figure 1 ).
In all, 86.66% patients with lactic acidosis presented with associated respiratory infection (3 patients with smearpositive pulmonary tuberculosis, the remainder were diagnosed with pneumonia based on clinical and radiological criteria). Seven had pancreatitis (raised plasma lipase levels). More than one associated condition was present in 11.1% of patients with lactic acidosis ( Table 3 ).
Outcome of Lactic Acidosis and Hyperlactatemia
In all, 22.2% of patients in the lactic acidosis group died. All patients who died from NRTI-induced lactic acidosis had a baseline CD4 count of <10 cells/mm 3 with average time of exposure to HAART of 40.4 weeks. The time to recovery in patients with symptomatic hyperlactatemia without lactic acidosis ranged from 2 weeks to 6 months (average 3 months). The time to recovery in survivors from lactic acidosis ranged from 3 weeks to 7 months (average 4 months).
Discussion
The use of combination ART to treat patients infected with the HIV has transformed the care of patients with HIV infection. However, this treatment is associated with increased morbidity and mortality from adverse events. Mitochondrial toxicity is one of the most frequently reported events presenting in the form of polyneuropathy, lipodystrophy, hyperlactatemia, and lactic acidosis syndrome. [6] [7] [8] [9] This report confirms the findings of previous studies that indicate that women more commonly experience hyperlactatemia and lactic acidosis.
The overall incidence rate of hyperlactatemia (31.79 cases per 1000 patient year) is higher than that reported by Bolhaar et al (20.2 cases per 1000 patient year) in Soweto, South Africa, 12 but the incidence rate among women in this cohort is similar to the Soweto cohort. The higher incidence in women compared to men is similar to the report from other resourcelimited settings. 10, 11, 14, 15 The median age (38 years) was similar to that reported from Durban, Soweto, and Botswana. [10] [11] [12] High BMI (>25 kg/m 2 ) at treatment initiation predicted the risk of hyperlactatemia or lactic acidosis in 40% of patients. The mean BMI (26.7 kg/m 2 ) at onset and following commencement of HAART differs to that reported in a Soweto cohort 12 where the mean BMI at baseline was 34.8 Kg/m 2 .
The mean length of time on treatment (9.2 months) before onset of symptoms and the commonest presenting symptoms in this cohort is similar to that reported by Ogedegbe et al (9 months) and Arenas-Pinto et al. 1, 14 The most common presenting symptoms were abdominal pain, loss of appetite, and paresthesias. The mean serum lactate level value at the onset of symptoms was similar to that reported by Arenas-Pinto et al and Wester et al. 11, 14 The median baseline CD4 counts in this cohort (79 cells/ mm 3 ) is lower than that reported by the lactic acidosis international group (248 cells/mm 3 ), 12 suggesting advanced HIV infection at HAART initiation. Advanced HIV infection has been previously reported as a possible risk factor for ART-associated mitochondrial toxicity events. 12 Associated comorbid conditions reported at the time of presentation may be due to either mitochondrial toxicity for example pancreatitis or the precipitating event of the hyperlactatemia or lactic acidosis. The comorbid conditions may have contributed to the final outcome in patients with the lactic acidosis. There were no fatalities in patients with hyperlactatemia without acidosis, but 22.2% of patients in the lactic acidosis group died. This is similar to other reports. 2, 4, 6, 9, [11] [12] [13] A high mortality was associated with concomitant pancreatitis and lactic acidosis together with an extremely low CD4 counts <5 cells/mm 3 ). All patients who died had a CD4 count of <10 cells/mm 3 and the lactate level >10 mmol/L similar to that reported by study from Johannesburg Hospital. 15 This suggests that the cause of mortality may be a combination of advanced HIV disease and complications of HIV treatment. There was no significant difference in the time to recovery of patients between the lactic acidosis and the hyperlactatemia without acidosis groups (3-4 months respectively).
The findings of this study are limited by its retrospective nature as not all patients may have been identified and the final cause of mortality was not definitively established pathologically.
The role of initiation of HAART at higher CD4 counts in the prevention of HAART-associated morbidity and mortality needs to be explored further. The role of associated conditions at the time of presentation with NRTI-induced lactic acidosis and hyperlactatemia without acidosis in the morbidity and mortality of this group needs to be determined.
Conclusions
A higher overall incidence of NRTI-induced hyperlactatemia or lactic acidosis was found in this cohort. The overall mortality due to lactic acidosis was 22%. All patients who died had a baseline CD4 count <10 cells/mm 3 at HAART initiation. Associated comorbid conditions at the time of presentation may portend a poor outcome in d4T-associated lactic acidosis.
